期刊
CANCER BIOLOGY & THERAPY
卷 11, 期 4, 页码 401-409出版社
LANDES BIOSCIENCE
DOI: 10.4161/cbt.11.4.14178
关键词
like kinase 1 (Plk1); hepatocellular carcinoma; RNA interference; short hairpin RNAs (shRNAs); cantionic liposome; apoptosis
类别
资金
- Hi-tech Research and Development Program (863 Program) of China [2007AA021008, 2009ZX09102-241]
- National Key Basic Research Program (973 Program) of China [2010CB529900]
Polo-like kinase 1 (Plk1) is a key cell cycle regulator that is frequently overexpressed in human hepatocellular carcinomas. Blockade of the Plk1 pathway has been reported to be capable of inducing antitumor effect. Here, plasmids containing U6 promoter-driven shRNAs against human Plk1 were constructed and transfected in human hepatocellular carcinoma cell line HepG2. ShRNA targeting Plk1 almost completely reduced Plk1 expression in HepG2 hepatocellular carcinoma cells, as confirmed by RT-PCR and western blot. As a consequence, HepG2 cells exhibited reduced proliferation and enhanced apoptosis in vitro. Most importantly, treatment with Plk shRNA-DOTAP : Chol complex significantly suppressed the growth of HepG2 xenografts, accompanied with phenotypic changes in tumor cells, including proliferation inhibition and apoptosis induction. Our study suggested that shRNA-mediated silencing of Plk1 might be a novel therapeutic approach against human hepatocellular carcinoma by inhibiting tumor cells proliferation and inducing apoptosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据